Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study

Launched by TAMPERE HEART HOSPITAL · Jan 27, 2025

Keywords

ClinConnect Summary

The Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study is looking to understand the causes of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in people who have coronary artery disease (CAD). Researchers want to find out if there are specific medical or treatment-related factors, as well as new genetic factors, that could increase the risk of these serious events in patients under 75 years old.

To participate, you need to be over 18 and live in the area of Pirkanmaa, Finland, where you are seeking treatment for CAD. You should have been diagnosed with CAD through specific heart imaging tests in the last three months. If you join the study, you’ll fill out a short survey about your health and lifestyle, have an electrocardiogram (ECG) to check your heart rhythm, and undergo some basic health checks like measuring your blood pressure. A blood sample may also be taken if you are under 76. The best part is that you won’t need to return for any follow-up visits, as the researchers will track your health using existing medical records. This study aims to improve our understanding of heart health and could lead to better prevention strategies for sudden cardiac issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \> 18 years
• • 2. A patient who lives in the area of 'Wellbeing Services County of Pirkanmaa' and seeks treatment for coronary artery disease (CAD).
• • 3. CAD is diagnosed with invasive coronary angiogram or computed tomography angiogram (CTA) which is evaluated by cardiologists based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results.
• • 4. An invasive coronary angiogram or CTA is done within three (3) months.
• • 5. Good or moderate everyday functional ability
• Exclusion Criteria:
• • 1. Life expectancy \<1 months.
• • 2. A significant valvular heart disease treated previously (endovascular or surgical) or requires treatment (endovascular or surgical) in the next three (3) months.
• • 3. Previously implanted cardioverter-defibrillators (ICD) or will be implanted in the next three (3) months.
• • 4. An active malignancy (ongoing treatment for a solid tumour, metastatic solid tumour, fast progressing haematological malignancy, or equal malignant disease).
• • 5. A significant neurodegenerative disease (dementia, Mini-Mental State Examination (MMSE) \<23 or equivalenneurodegenerative disease affecting everyday functional ability, like ALS, myositis, prograded MS-disease or Parkinson's disease).
• • 6. Intellectual disability or a significant disability affecting cognitive functions
• • 7. Do-not-resuscitate (DNR) treatment decision
• Subgroup with blood samples:
• • Blood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time\>110ms in the latest ECG.